P17.22.B SILMET TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE STAT3 INHIBITOR SILIBININ IN PREVENTING INTRACRANIAL RECURRENCE AFTER COMPLETE RESECTION OF A SINGLE BRAIN METASTASIS FROM NON-SMALL-CELL LUNG CANCER (NSCLC) OR BREAST CANCER | Publicación